scispace - formally typeset
Open AccessJournal ArticleDOI

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments.

Shin Jie Yong
- 01 Jan 2021 - 
- Vol. 53, Iss: 10, pp 737-754
Reads0
Chats0
TLDR
In this paper, a review of the literature on long COVID-19 syndrome is presented, which is driven by long-term tissue damage (e.g. lung, brain, and heart) and pathological inflammation (i.e. from viral persistence, immune dysregulation, and autoimmunity).
Abstract
Long COVID or post-COVID-19 syndrome first gained widespread recognition among social support groups and later in scientific and medical communities. This illness is poorly understood as it affects COVID-19 survivors at all levels of disease severity, even younger adults, children, and those not hospitalized. While the precise definition of long COVID may be lacking, the most common symptoms reported in many studies are fatigue and dyspnoea that last for months after acute COVID-19. Other persistent symptoms may include cognitive and mental impairments, chest and joint pains, palpitations, myalgia, smell and taste dysfunctions, cough, headache, and gastrointestinal and cardiac issues. Presently, there is limited literature discussing the possible pathophysiology, risk factors, and treatments in long COVID, which the current review aims to address. In brief, long COVID may be driven by long-term tissue damage (e.g. lung, brain, and heart) and pathological inflammation (e.g. from viral persistence, immune dysregulation, and autoimmunity). The associated risk factors may include female sex, more than five early symptoms, early dyspnoea, prior psychiatric disorders, and specific biomarkers (e.g. D-dimer, CRP, and lymphocyte count), although more research is required to substantiate such risk factors. While preliminary evidence suggests that personalized rehabilitation training may help certain long COVID cases, therapeutic drugs repurposed from other similar conditions, such as myalgic encephalomyelitis or chronic fatigue syndrome, postural orthostatic tachycardia syndrome, and mast cell activation syndrome, also hold potential. In sum, this review hopes to provide the current understanding of what is known about long COVID.

read more

Citations
More filters
Journal ArticleDOI

Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis

TL;DR: In this paper , a meta-analysis of proportions was conducted to pool Freeman-Tukey double arcsine transformed proportions using the random-effects restricted maximum-likelihood model to quantify the proportion of individuals experiencing fatigue and cognitive impairment 12 or more weeks following COVID-19 diagnosis.
Journal ArticleDOI

The Lancet Commission on lessons for the future from the COVID-19 pandemic

TL;DR: The COVID-19 Commission report as mentioned in this paper provides a conceptual framework for understanding pandemics and proposes guideposts for strengthening the multilateral system to address global emergencies and to achieve sustainable development.
Journal ArticleDOI

Persistent COVID-19 symptoms in a community study of 606,434 people in England

TL;DR: In this article , the authors used data from rounds 3-5 of the REACT-2 study (n = 508,707; September 2020- February 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms.
Journal ArticleDOI

Pathophysiology and mechanism of long COVID: a comprehensive review

TL;DR: A comprehensive review of the putative pathophysiology underlying the persisting symptoms of long COVID found that organ damage from the acute infection phase likely accounts for symptoms, and specific long-lasting inflammatory mechanisms have been proposed, as well.
Journal ArticleDOI

Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study

TL;DR: In this article , the authors analyse the nature, prevalence, and severity of long-term symptoms related to COVID-19, while correcting for symptoms present before SARS-CoV-2 infection and controlling for the symptom dynamics in the population without infection.
References
More filters
Journal ArticleDOI

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia.

TL;DR: In this paper, the authors investigated the risk factors for fibrotic-like changes in the lung at 6-month follow-up chest CT of survivors of severe COVID-19 pneumonia.
Journal ArticleDOI

Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis.

TL;DR: A significant association between lymphopenia, thrombocytopenia and elevated levels of CRP, PCT, LDH, D-dimer and COVID-19 severity is found and has the potential to be used as an early biomarker to improve the management of CO VID-19 patients.
Journal ArticleDOI

Cerebral Micro-Structural Changes in COVID-19 Patients - An MRI-based 3-month Follow-up Study.

TL;DR: Findings revealed possible disruption to micro-structural and functional brain integrity in the recovery stages of COVID-19, suggesting the long-term consequences of SARS-CoV-2.
Journal ArticleDOI

Preliminary evidence on long COVID in children.

TL;DR: In this article, a large cohort of 1733 patients from Wuhan found persistent symptoms in 76% of patients 6 months after initial diagnosis of acute COVID•19, with the exception of an earlier description of five children with Long COVID in Sweden.
Related Papers (5)
Trending Questions (1)
What are the most effective treatments for long COVID?

The paper mentions that personalized rehabilitation training and therapeutic drugs repurposed from similar conditions hold potential as treatments for long COVID. However, it does not provide specific information on the most effective treatments.